KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm. 2025;39(3):165-170 / www.klinickafarmakologie.cz 170 PŘEHLEDOVÉ ČLÁNKY Léčba polymorbidních pacientů s roztroušenou sklerózou 18. Thormann A, Sřrensen PS, Koch-Henriksen N, et al. Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. Neurology. 2017;89(16):1668-1675. 19. Zhang T, Tremlett H, Leung S, et al. Examining the effects of comorbidities on disease-modifying therapy initiation and choice in MS. Mult Scler Relat Disord. 2016;8:146-152. 20. Magyari M, Sřrensen PS. Comorbidity in Multiple Sclerosis. Front Neurol. 2020;11:851. 21. Geraldes R, Ciccarelli O, Barkhof F, et al. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Pract Neurol. 2018;18(6):441-452. 22. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010;74(13):1041-1047. 23. Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol. 2012;72(2):234-240. 24. Feinstein A, Magalhaes S, Richard JF, et al. The link between multiple sclerosis and depression. Nat Rev Neurol. 2014;10(9):507-517. 25. Tettey P, Simpson S Jr, Taylor BV, et al. An approach to studying co-occurring autoimmune diseases in multiple sclerosis. Mult Scler Relat Disord. 2014;3(3):254-265. 26. Luna G, Alping P, Burman J, et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2020;77(2):184-191. 27. Skou ST, Mair FS, Fortin M, et al. Multimorbidity. Nat Rev Dis Primers. 2022;8:48. 28. Cree BAC, Hollenbach JA, Bove R, et al. Silent progression in disease activity–free relapsing MS. Ann Neurol. 2019;85(5):653-666. 29. Braley TJ, Segal BM. Obstructive sleep apnea is associated with fatigue in multiple sclerosis. J Clin Sleep Med. 2014;10(2):155-162. 30. Kurth T, Mohamed S, Maillard P, et al. Headache, migraine, and structural brain lesions and function: population-based Epidemiology of Vascular Ageing–MRI study. BMJ. 2011;342:c7357. 31. Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in MS. JAMA Neurol. 2019;76(5):536-541. 32. He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307-316. 33. Selmaj K, Cree BAC, Barnett M, et al. Multiple sclerosis: time for early treatment with high-efficacy agents. J Neurol. 2024;271(1):105-115. 34. Zeposia (ozanimod) – Summary of Product Characteristics (SmPC) [Internet]. [cited 2025-08-08]. European Medicines Agency. Available from: https://www.ema.europa.eu/ en/documents/product-information/zeposia-epar-product-information_en.pdf. 35. Ocrevus (ocrelizumab) – Summary of Product Characteristics (SmPC) [Internet]. [cited 2025-08-08]. European Medicines Agency. Available from: https://www.ema.europa.eu/ en/documents/product-information/ocrevus-epar-product-information_en.pdf. 36. Kesimpta (ofatumumab) – Summary of Product Characteristics (SmPC) [Internet]. [cited 2025-08-08]. European Medicines Agency. Available from: https://www.ema.europa.eu/ en/documents/product-information/kesimpta-epar-product-information_en.pdf. 37. Briumvi (ublituximab) – Summary of Product Characteristics (SmPC) [Internet]. [cited 2025-08-08]. European Medicines Agency. Available from: https://www.ema.europa.eu/ en/documents/product-information/briumvi-epar-product-information_en.pdf. 38. Brummer T, Ruck T, Meuth SG, et al. Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders. Ther Adv Neurol Disord 2021;14: 17562864211035542. 39. Konen FF, Witte T, Ernst D, et al. Management of disease-modifying therapies in multiple sclerosis and comorbid rheumatoid arthritis. Neurol Res Pract 2025;7(1):48. 40. Rejdak K, Szklener S, Korchut A, et al. Cladribine in myasthenia gravis: a pilot open-label study. Eur J Neurol. 2020;27(3):586-589. 41. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) [Internet]. [cited 2025-08-11]. Merck Healthcare KgaA. Available from: https://clinicaltrials. gov/study/NCT06463587/. 42. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353:1912-1925. 43. Targan SR, Feagan BG, Fedorak RN, et al. ENCORE trial – natalizumab for active Crohn’s disease. Gastroenterology. 2007;132(5):1672-1683. 44. Delcoigne B, Kopp TI, Arkema EV, et al. Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers. RMD Open. 2023;9(1):e002924. 45. Li L, Aviña-Zubieta JA, Bernstein CN, et al. Risk of Multiple Sclerosis Among Users of Antitumor Necrosis Factor α in 4 Canadian Provinces: A Population-Based Study. Neurology. 2023;100(6):e558-e567. 46. Konen FF, Möhn N, Witte T, et al. Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. Autoimmun Rev. 2023;22(5):103312. 47. Mason A, Fragapane L, Toledo-Nieves Z, et al. Use of Calcitonin Gene-Related Peptide Monoclonal Antibodies for the Treatment of Migraines in Individuals With Multiple Sclerosis. Int J MS Care 2024;26(3):104-107. 48. Nociti V, Romozzi M, Annovazzi P, et al. Effectiveness, safety, and impact on multiple sclerosis course of anti-CGRP monoclonal antibodies. J Neurol Sci. 2025;469:123392. 49. Di Tullio F, Odorici G, Lasagni C, et al. Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis. Dermatol Ther. 2020;33(6):e13943. 50. Eksin MA, Erden A, Güven SC, et al. Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review. Immunotherapy. 2022;14(6):401-408. 51. Elgenidy A, Elkady A, El-Dahshan M, et al. Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 patients. Front Neurolw 2024;15:1380654. 52. Kolčava J, Lasotová N, Vlčková E, et al. Validation of DYsphagia in MUltiple Sclerosis questionnaire – Czech version of DYMUS. Čes Slov Neurol Neurochir 2020;83/116(3):285-290. 53. Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96-120. 54. Thakolwiboon S, Mills EA, Yang J, et al. Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration. Front Aging. 2023;4:1234572. 55. van der Walt A, Strijbis EMM, Bridge, F et al. Advancing multiple sclerosis management in older adults. Nat Rev Neurol. 2025;21:432-448. 56. Corboy JR, Fox RJ, Kister I, et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol. 2023;22(7):568-577. 57. Coerver EME, Fung WH, de Beukelaar J, et al. Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial. JAMA Neurol. 2025;82(2):123-131. 58. Lee S, Scheu R, Mateen FJ. Adults 55 Years and Older with Multiple Sclerosis (MS) Treated with Ocrelizumab: Characteristics and Outcomes Over More Than 13,000 Person-Months (Abstract P10-1.013). Neurology. 2025;104(7):Suppl1.
RkJQdWJsaXNoZXIy NDA4Mjc=